Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan
Sign Up to like & getrecommendations! Published in 2017 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-017-0640-5
Abstract: BackgroundWhether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of… read more here.
Keywords: associated lower; dpp4i users; lower risk; study ... See more keywords